AES believes this is high public health priority as it will save lives i.e., to identify patients at higher risk for SUDEP and thus particularly in need of pharmaco-treatments or preventative devices (AICD) or patient surveillance. It will, however, be a major challenge due to ascertainment and low (sporadic) sample size worldwide. A genetic approach to identify genes associated with SUDEP is laudable though it seems doubtful that ALL SUDEP results from a genetic mutation and instead genomic pre-disposition (susceptibility variants, SNPs) and other factors may contribute.
Why would this research priority transform epilepsy research, our understanding of the epilepsies, and/or treatment of the epilepsies? :
Idea No. 126